NEW YORK (GenomeWeb News) – French biopharmaceutical firm Transgene today and the Ligue nationale contre le cancer, or the French league against cancer, today announced an agreement to identify membrane-specific targets from gene expression data in order to develop new oncology biotherapies.
The data was collected by Ligue from more than 4,800 tumors.
The Lique initiated a program in 2000 called Carte d'Identité des Tumeurs (CIT), or identity card of tumors, to analyze the genes and chromosomal alternations in several cancers in order to better diagnose disease and predict disease evolution. The program also hopes to improve the ability to predict response to therapy and to improve therapeutic follow-up.
CIT enables the identification of biomarkers associated with specific tumor-specific cellular mechanisms, and the Ligue and Transgene hope to accelerate the development of specific drugs for certain tumors, they said.